EGFR mutations and molecularly targeted therapy: A new era in the treatment of lung cancer

Nature Clinical Practice Oncology

Volumn 3, Issue 4, 2006, Pages 170-171

  Dowell, Jonathan E ^a   Minna, John D ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PLACEBO; PROTEIN TYROSINE KINASE;

CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TARGETING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE FREQUENCY; GENE TARGETING; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; METASTASIS POTENTIAL; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEX DIFFERENCE; SOMATIC MUTATION; SURVIVAL RATE; SURVIVAL TIME; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; GENE DOSAGE; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33645709473     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0476     Document Type: Review

References (10)

1. Fukuoka M et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21: 2237-2246
2. Kris MG et al. (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290: 2149-2158
3. Shepherd FA et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132
4. Thatcher N et al. (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366: 1527-1537
5. Lynch TJ et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139
6. Paez JG et al. (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497-1500
7. Dowell JE and Minna JD (2004) The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy. Nat Clin Pract Oncol 1: 2-3
8. Tsao MS et al. (2005) Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353: 133-144
9. Hirsch FR et al. (2005) Molecular analysis of EGFR gene copy number, EGFR expression and Akt activation status in advanced non-small-cell lung cancer treated with gefitinib or placebo (ISEL trial) [abstract #268a]. In Proceedings of the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics: 2005 November 14-18; Philadelphia, 124-125
10. Cappuzzo F et al. (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97: 643-655